BIOPHARMACEUTICAL SECTOR

Slides:



Advertisements
Similar presentations
ETHICS AS CULTURE KEY ELEMENTS Stage One (primary) – Key Elements of a Culture of Ethics Appoint an ethics program manager to oversee your ethics-related.
Advertisements

Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
Responsible CarE® Codes of Management Practices Overview
HR Manager – HR Business Partners Role Description
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
First Evaluation of Good Governance for Medicines Programme Brief Summary of Findings.
ICS 417: The ethics of ICT 4.2 The Ethics of Information and Communication Technologies (ICT) in Business by Simon Rogerson IMIS Journal May 1998.
ISO Richard Welford CSR Asia © CSR Asia 2011.
Company Confidential 1 © 2007 Nokia Nokia/AOG Industry Collaboration in the ICT sector Abi Oxley Green January 28th.
Health Career Recruitment and Retention Service-Based Learning.
Corporate Governance in the Caribbean Environment “The Caribbean Corporate Governance Forum” Trevor E Blake General Manager – ECSE.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
The Importance of Promoting Codes of Ethics to Stakeholders.
Nuclear Security Culture William Tobey Workshop on Strengthening the Culture of Nuclear Safety and Security, Sao Paulo, Brazil August 25-26, 2014.
Strategic Approaches to Improving Ethical Behavior
CCC’s Bi-Monthly Member Meeting GHP Operational Plan 2016 By: Soeung Saroeun, ED EL Sotheary, HOP 08 December 2015, KSSA, Phnom Penh Vision: Sustainable.
PROTECTING THE INTERESTS OF CONSUMERS OF FINANCIAL SERVICES Role of Supervisory Authorities Keynote Address to the FinCoNet Open Meeting 22 April 2016.
Science & Technology for National Progress in African Region: Highlights of Regional Strategy and Action Professor Gabriel B. Ogunmola, FAS President,
Global Dialogue on Customs Capacity Building 04 April 2007 © 2007 IBM Corporation Benefits of Supply Chain Security and Trade Facilitation: The IBM Experience.
Project: EaP countries cooperation for promoting quality assurance in higher education Maria Stratan European Institute for Political Studies of Moldova.
UNGGIM – PRIVATE SECTOR NETWORK. AGENDA > OVERVIEW OF PRIVATE SECTOR >PURPOSE AND VISION OF PRIVATE SECTOR NETWORK > STRUCTURE AND TERMS OF REFERENCE.
Civil Society Participation and Contribution to the UNCAC Review Process Towards Transparency – TI National Contact Vietnam UNCAC Self Assessment Process:
UHC2030: working together to strengthen health systems
Today’s managers & leaders are challenged unlike any of the past generations in their roles.
JMFIP Financial Management Conference
Mgt Project Portfolio Management and the PMO Module 8 - Fundamentals of the Program Management Office Dr. Alan C. Maltz Howe School of Technology.
The New Performance Appraisal Tool for RCs and UNCTs
Principles of Good Governance
The IFPMA Code and how to set up a national self-regulation system Presentation to China/EU Pharmaceutical Industry Forum 17 May 2017, Shanghai, China.
The IVD Australia Code of Conduct Edition 2.1
MODULE ONE: UNDERTAKING A STATUS ASSESSMENT
Member Body Compliance Program
MEDICAL DEVICE & BIOPHARMACEUTICAL SECTORS
MGMT 452 Corporate Social Responsibility
Flag and Logo USAID/Pakistan Alumni Association Discussion on New Directions October 1, 2016.
Principles Of Women Empowerment
5 OCTOBER 2015 MANILA, PHILIPPINES
Department of Political Science & Sociology North South University
Accreditation Canada Medicine Accreditation 2016.
HEALTH IN POLICIES TRAINING
Ulrich’s model of HR.
Построение культуры integrity в компании Aнар Каримов партнёр «ЭКВИТА»
Communications Strategy
Cover Slide Interactive, Distributor Case Study
Human Resources Competency Framework
2017 On the Ball Initiative On the Ball is a collaborative HSE initiative designed to refresh and re-energise HSE , with the ultimate goal of achieving.
Competency Based Learning and Development
Inclusive Governance and Multiplying Impact
Support for the AASHTO Committee on Planning (COP) and its Subcommittees in Responding to the AASHTO Strategic Plan Prepared for NCHRP 8-36, TASK 138.
SAI Engagement with External Stakeholders
Research for all Sharing good practice in research management
THE independent evaluation office of Undp Independence, credibility and use IPDET, 30 June 2014 Indran A. Naidoo Director.
Statistics Governance and Quality Assurance: the Experience of FAO
Cover Slide Interactive, Distributor Case Study
The Value from and Responsibility for ensuring Ethical Codes of Conduct: Industry and Association Responsibilities.
Ethics as Culture key elements
SwafS Ethics and Research Integrity
Introduction to TransCelerate
Chapter 8 Developing an Effective Ethics Program
Chapter 10 Globalization of Ethical Decision-Making
Product Stewardship Institute Advisory Council Meeting The Lenox Hotel – Boston, MA September 14, 2012.
Commission strategy to
Employee engagement Delivery guide
Industry Induction Course
SwafS Ethics and Research Integrity
A Guide to the Sharing Information on Progress (SIP)
Environment and Development Policy Section
Ethics as Culture key elements
Yvette Connor Strategic Risk Management Engagement Leader
National Union Management Consultation Committee - Drug Manufacturing Inspection Transformation May 16, 2017 Regulatory Operations and Regions Branch.
Presentation transcript:

BIOPHARMACEUTICAL SECTOR CODE IMPLEMENTATION WORKSHOP (7 SEPTEMBER) BIOPHARMACEUTICAL SECTOR Introductory Remarks Ms. Lynn Costa, Project Overseer Business Ethics for APEC SMEs Initiative & Senior Advisor, U.S. Department of Commerce

BIOPHARMACEUTICAL SECTOR CODE IMPLEMENTATION WORKSHOP (7 SEPTEMBER) BIOPHARMACEUTICAL SECTOR Participant Introductions NAME │ POSITION │ ORGANIZATION │ ECONOMY

BIOPHARMACEUTICAL SECTOR Driving Code Implementation: CODE IMPLEMENTATION WORKSHOP (7 SEPTEMBER) BIOPHARMACEUTICAL SECTOR Driving Code Implementation: Governance, Alignment, & Member Adherence

A Six Year Journey from Mexico City to Hanoi

Widespread Industry Association Code Adoption

Successful Industry Assn Code Implementation The “Big Three” in Successful Industry Assn Code Implementation Code Governance – is it legitimate and alive… Code Alignment – is it a quality code of ethics… Member Implementation – is it being adhered to by enterprises in daily business practice… + External Engagement – is the code understood and embraced by other stakeholders in the health system…

CODE GOVERNANCE Strong leadership commitment, membership endorsement, and overall governance, but… A decline in code dissemination to external stakeholders and limited code trainings / one-on-one assistance suggests resource challenges.

CODE ALIGNMENT A genuine success story: the region is aligning with the APEC Mexico City Principles! 81% report the code embraces all six principles Alignment numbers are increasing each year… 11% decrease in the number of associations that make training available to HCPs / other groups

MEMBER IMPLEMENTATION APEC monitoring continues to improve… 76% of associations indicate the code has performed excellent or well, with at least 69% reporting a majority of members follow the code Non-member dilemma remains a key challenge Philippines (PHAP) pilot enterprise survey

APEC Biopharmaceutical Working Group on Ethics CO-CHAIRS PANEL Ms. Chris Nikidis INDUSTRY CO-CHAIR APEC Biopharmaceutical Working Group on Ethics CANADA Ms. Rocio Delgado GOVERNMENT CO-CHAIR PERU Dr. Kenneth Hartigan-Go HCP CO-CHAIR THE PHILIPPINES Mr. Russell Williams PATIENT CO-CHAIR

KEY QUESTIONS: What does success in driving code implementation look like to you? Consider opportunities and challenges. What is my responsibility to ensure success in driving code implementation?

INTERACTIVE EXERCISE What does success in driving code implementation look like to you? Consider opportunities and challenges. What is my responsibility to ensure success in driving code implementation? Designate a table facilitator, ten minute discussion, then your facilitator will report back to the full workshop.

INTERACTIVE EXERCISE / TABLE FEEDBACK Political Leadership Internal training and awareness building Role of civility society in mobilzing change self-regulation is a responsibility Training of medical sales representatives / October collaboration opportunity in Beijing Strengthening focus on daily business practices and changing cultural approaches Achieving industry code alignment across health systems / collaboration with government to achieve alignment in best practices Commit to make issue more interactive and engagement across different settings Tone at the top across multiple economies and settings / standard approach Collective understanding and approach, Forums for dialogue, consultative and partner approach, strengthening and building a positive brand for the sector Peer to peer approach Stakeholders to accept and internalize Codes: include in university curriculm Have stakeholders embrace that ethical behaviour is important Ownership and accountability-align on the success of implementation Cultural change- how can we influence Training both internally and externally Response to increase transparency –reframe in the broader society requirement Tone from the top Dissemination Reconcile laws and self regulation Stakeholders are all aligned on common ethical practices Tracking and monitoring code implementation How do we effectively share with our stakeholders Put the patient at the center of the conversation around strengthening ethical business practices. How to perform multi-sectoral training in limited resource settings? Sharing information across borders on best KEN: Scale our efforts and continue major objectives CHRIS: Build better training and outreach program. Tools and resources. ROCIO: Aligning codes of ethics, minimize gaps within health systems. Trust-based approach. RUSSELL: Focus on measurement and metrics to assess progress. Where can we improve? Think about expanding commit

COLLABORATION IN VIET NAM MULTI-STAKEHOLDER COLLABORATION IN VIET NAM TO STRENGTHEN ETHICAL BUSINESS PRACTICES

ADVANCING CODE OF ETHICS IMPLEMENTATION BREAKOUT SESSIONS ON ADVANCING CODE OF ETHICS IMPLEMENTATION 11:30-12:30 / 13:30-15:00 WHERE SHOULD I GO? Introductory Course: Song Hong Room 1 & 2 (same room) Advanced Course: Song Lo / Thao Room (across hallway) Note: Simultaneous interpretation only available in Introductory Course room PLEASE REMAIN IN YOUR CHOSEN COURSE

11:30-12:30 / 13:30-15:00 INTRODUCTORY BREAKOUT SESSIONS (COURSE A) ADVANCING CODE OF ETHICS IMPLEMENTATION 11:30-12:30 / 13:30-15:00 SCHEDULE OF MODULES Internal Considerations (Deborah, Amy, Ted, Busakorn, DD, Janet, Sofie) External Considerations (Katsumi, Rafizah, Cris, Thuy, Neil) Time Permitting: Individual / Small Group Mentor Sessions

INTERNAL CONSIDERATIONS MODULE ONE: INTERNAL CONSIDERATIONS

OVERVIEW This workshop is intended to assist economies who are at earlier stages of developing and implementing a Code of Practice by their member companies and other companies. We are going to work on three Case studies together, designed to stimulate thinking and discussion, in the imaginary country “Malicuria”: Case 1 – No Code of Practice – how to start this process and engage appropriate stakeholders Case 2 – Code of Practice recently adopted, but implementation variable and needs strengthening Case 3 – A Code of Practice has been adopted; how to maintain implementation and keep the Code up to date

11.00-11.15 Line-up Ice Breaker & Group Setting COURSE A TIMELINE 11.00-11.15 Line-up Ice Breaker & Group Setting 11.15-11.20 Introduction to Malicuria 11.20-11.55 Case study work in 3 groups (one Case study per group) 11.55-12.25 Presentation of results & discussion (5 + 5 min per group) 12:25-12:30 Wrap-up and close

Each group will have two facilitators to assist your discussions: YOUR FACILITATORS Each group will have two facilitators to assist your discussions: Case Study 1: Sofie Melis and Duangduen Sahavechaphan Case Study 2: Amy Huang and Deborah Monk Case Study 3: Teodoro Padilla & Busakorn Lerswatanasivalee

BIOPHARMACEUTICAL SECTOR CODE IMPLEMENTATION WORKSHOP (7 SEPTEMBER) BIOPHARMACEUTICAL SECTOR LUNCH BREAK LOCATION: OVEN D’OR RESTAURANT (12:30 – 13:30)

EXTERNAL CONSIDERATIONS MODULE TWO: EXTERNAL CONSIDERATIONS

Healthcare Professionals Ethical Business Practice is Everybody’s Business Government Industry Distributors Healthcare Professionals Patients Media Industry alone cannot achieve ethical business practices. There should be continued engagement and partnership between all stakeholders to ensure an ethical environment.

The Industry Companies and associations Unethical business practices by one or a few enterprises can damage the reputation of an entire industry within an economy or across borders. As such, it is important for companies and associations to promote Code of Ethics to all enterprises, even if they are not association members. Furthermore, collaboration and unity presented to other stakeholders can place industry in a strong position to continue promoting high ethical standards.

Government Stakeholders Regulators, Enforcers, Customers, Payers, Champions Governments across the 21 APEC economies have endorsed the Mexico City Principles, but many of the relevant government stakeholders may still not have heard about them. Potential stakeholders at national/regional levels: Ministry/Department of Health Food and Drug Administration Pricing and Reimbursement/Procurement Agencies Anti-Corruption Authorities Ministry of Industry/Trade Others? Need for continued and ongoing engagement

Healthcare Professionals (HCPs) and Associations/Hospitals Customers – Potential risk of exposure to Unethical Practices Industry interactions with HCPs can present most significant risks Industry interactions with purchasing agents in Hospitals, Institutions and Corporations also a point of risk Industry should inform HCPs and their representative associations about Codes of Ethics to ensure HCPs understanding of the high ethical environment Industry should partner with HCPs to motivate change In many of the APEC Economies, HCPs are also Government employees

Intermediaries (Distributors / Supply Chain) Intermediaries – Ensure compliance with ethical practices Important actors in the supply chain to ensure safety, quality, integrity and compliance of pharmaceuticals from manufacturing all the way to the patient Like HCPs, all intermediaries (including distributors and other actors in the supply chain) must have full understanding of industry Codes of Ethics to ensure strict compliance with the most updated rules (following national and global standards) and that they do not inadvertently facilitate unethical business practices

Patients / Patient Organizations Voice for Patients Shared goal of ensuring that medical decisions are made in the best interests of patients, aligned with the APEC Mexico City Principles Patient groups need to be made aware of and understand the purpose of Codes of Ethics, and to see results (change) following implementation In turn, Patient Groups can serve as strong advocates for Codes of Ethics with all other stakeholders, patients and broader society

Working towards a Consensus Framework Aims to enhance credibility, dialogue, trust and respect between governments, organizations, professionals, institutions and the healthcare system and ultimately to improve health outcomes. Established to demonstrate the common commitment to professional integrity and appropriate ethical interactions among the signatory partners so that decisions are made in the best interests of patients. Ultimately, we can build trust and promote transparency by starting with what we have in common – where everyone is comfortable – and developing standards that allow us all to build relationships that are mutually beneficial.

EXTERNAL CONSIDERATIONS TIME PERMITTING: INDIVIDUAL MENTOR SESSIONS MODULE TWO: EXTERNAL CONSIDERATIONS HANDOUT EXERCISE TIME PERMITTING: INDIVIDUAL MENTOR SESSIONS

BIOPHARMACEUTICAL SECTOR CODE IMPLEMENTATION WORKSHOP (7 SEPTEMBER) BIOPHARMACEUTICAL SECTOR NETWORKING BREAK (15:00 – 15:30)

INTERACTIVE, MULTI-STAKEHOLDER CASE STUDIES 15:30-17:00 LEAD FACILITATOR Ms. Laura Giussani, ‎Ethics and Compliance Eli Lilly and Company

15:30-17:00 INTERACTIVE, MULTI-STAKEHOLDER CASE STUDIES SCHEDULE OF CASE STUDIES (45 MINUTES EACH) Case Study One: Traditional Industry Interactions Case Study Two: Distributors

TRADITIONAL INDUSTRY INTERACTIONS CASE STUDY ONE: TRADITIONAL INDUSTRY INTERACTIONS 45 MINUTES HANDOUT EXERCISE

CASE STUDY TWO: DISTRIBUTORS 45 MINUTES HANDOUT EXERCISE

Overview This exercise is centered on the increasingly critical and complex role that Distributors play on behalf of Pharmaceutical Companies. A list of potential activities conducted by Distributors will be displayed. Each table will be assigned two activities to discuss and then a representative from each table will: Recommend where each activity should be placed in a Risk Grid Explain the rationale for the proposed placement (i.e., create a risk statement) Offer some possible controls to address the risk Ten minutes will be reserved for attendees to discuss any additional activities that Distributors may conduct on behalf of companies. All attendees will be invited to share specific experiences of how they have worked with Distributors to strengthen their relationships and address possible risks.

Activities Activities Distributors may conduct for or on behalf of Pharmaceutical Companies: Product Distribution and Promotion HCP Symposiums and Related Travel Contract Sales Organization (CSO) Import/Export Activities Product Registration Patient Support Programs Marketing Authorization Holder Hiring entity for in-country personnel Provider of office space for in-country personnel Other product-related activities such as Implementing anti-counterfeiting programs Implementing pricing strategies with end clients Providing support in securing government pricing and/or reimbursement

Fair Market Value (FMV) Others (e.g., Reputation) Risk Considerations Anti-Corruption Laws Fair Market Value (FMV) Privacy Labor Laws Others (e.g., Reputation) Activity 1 2

1 2 3 4 5 6 7 8 9

Shared Practices What has been an effective approach and/or control for you?

BIOPHARMACEUTICAL SECTOR CODE IMPLEMENTATION WORKSHOP (7 SEPTEMBER) BIOPHARMACEUTICAL SECTOR CLOSING OBSERVATIONS Ms. Chrisoula Nikidis Vice President, Ethics, Integrity and Governance Innovative Medicines Canada

BIOPHARMACEUTICAL SECTOR CODE IMPLEMENTATION WORKSHOP (7 SEPTEMBER) BIOPHARMACEUTICAL SECTOR GUIDANCE FOR PLENARY DIALOGUE (8 SEPTEMBER) Mr. Andrew Blasi Associate Director C&M International

BIOPHARMACEUTICAL SECTOR RECEPTION LAKE SIDE GARDEN, SHERATON HANOI CODE IMPLEMENTATION WORKSHOP (7 SEPTEMBER) BIOPHARMACEUTICAL SECTOR PLEASE JOIN THE BIOPHARMACEUTICAL SECTOR RECEPTION LAKE SIDE GARDEN, SHERATON HANOI (17:30-19:00)